Phase II Clinical trial of personalized peptide vaccine for patients with maligant tumors (gastrointestinal cancers, hepato-biliary-pancreatic cancers, thoracic malignant tumors, non-epithelial malignant tumors, genitourinary cancers, gynecological cancers, breast cancers, and rare cancers) - Effect of extended interval dosing on immune responses - - Personalized peptide vaccine trial for patients with maligant tumors - Effect of extended interval dosing on immune responses

Kurume University CanCER Vaccine Center0 个研究点目标入组 800 人开始时间: 2013年7月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The following patients must be excluded: 1) Patients with severe underlying diseases (active and severe infectious diseases, cardiovascular diseases, respiratory diseases, renal diseases, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) Patients who are pregnant, nursing, or want to be pregnant. Patients with no acceptance of use of effective contraception during and at least 70 days after study participation. 4) Past history of usage of peptides employed in the study. 5) Patients who are judged inappropriate for enrollmwnt in this study by the attending doctors.

发起方

Kurume University CanCER Vaccine Center